In Brief: U.S. Surgical/EndoTex
This article was originally published in The Gray Sheet
Executive Summary
U.S. Surgical/EndoTex: Agreement gives USSC a 90-day option to acquire EndoTex Interventional Systems' technology relating to covered stent, stent graft and "related delivery system technology" for abdominal aortic aneurysms (AAA) and AV fistula applications, USSC says. Following due diligence by USSC, the firm will either "consummate the transaction or convert its initial payment into an equity investment," at the end of the 90-day period. Menlo Park, California-base EndoTex expects to begin clinical trials in the third quarter "in conjunction" with USSC, evaluating the covered stent in AAA and aneurysm repair...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.